Spruce Biosciences (SPRB) Shares Outstanding (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Shares Outstanding (Entity) of $1.4 million for Q1 2026, up 143.77% year-over-year from $562943.0 in Q1 2025, and up 79.01% quarter-over-quarter from $766598.0 in Q4 2025.
Spruce Biosciences (SPRB) Shares Outstanding (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Shares Outstanding (Entity) for 8 consecutive years, with $1.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 143.77% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $1.4 million (up 143.77% YoY), while the FY2025 annual figure was $766598.0, up 36.18% from the prior year.
- Shares Outstanding (Entity) climbed to $1.4 million in Q1 2026 per SPRB's latest filing, from $766598.0 in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $1.4 million in Q1 2026 and bottomed at $313160.0 in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $550258.7 across 5 years, with a median of $548593.0 in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) advanced 0.46% — and 2026, when it surged 143.77%.
- Spruce Biosciences' Shares Outstanding (Entity) stood at $314601.0 in 2022, then soared by 73.85% to $546928.0 in 2023, then grew by 2.93% to $562943.0 in 2024, then soared by 36.18% to $766598.0 in 2025, then jumped by 79.01% to $1.4 million in 2026.
- Business Quant data shows SPRB's Shares Outstanding (Entity) at $1.4 million in Q1 2026, $766598.0 in Q4 2025, and $563491.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | 2.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.37 Mn |
| Mar 31, 2026 | 1.37 Mn |
| Dec 31, 2025 | 766,598.00 |
| Sep 30, 2025 | 563,066.00 |
| Jun 30, 2025 | 591,137.00 |
| Mar 31, 2025 | 585,786.00 |
| Dec 31, 2024 | 550,062.00 |
| Sep 30, 2024 | 550,564.00 |
| Jun 30, 2024 | 548,706.00 |
| Mar 31, 2024 | 547,813.00 |
| Dec 31, 2023 | 513,341.00 |
| Sep 30, 2023 | 542,674.00 |
| Jun 30, 2023 | 540,504.00 |
| Mar 31, 2023 | 425,229.00 |
| Dec 31, 2022 | 313,616.00 |
| Sep 30, 2022 | 314,058.00 |
| Jun 30, 2022 | 313,170.00 |
| Mar 31, 2022 | 313,152.00 |
| Dec 31, 2021 | 311,408.00 |
| Sep 30, 2021 | 311,484.00 |